Genix Pharmaceuticals Corporation (GENX.V)
| Previous Close | 0.0600 |
| Open | 0.0600 |
| Bid | 0.0600 x N/A |
| Ask | 0.0650 x N/A |
| Day's Range | 0.0600 - 0.0600 |
| 52 Week Range | 0.0200 - 0.0800 |
| Volume | |
| Avg. Volume | 16,169 |
| Market Cap | 3.553M |
| Beta (5Y Monthly) | -0.60 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0700 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Simply Wall St.Genix Pharmaceuticals First Quarter 2024 Earnings: CA$0.001 loss per share (vs CA$0.004 loss in 1Q 2023)
Genix Pharmaceuticals ( CVE:GENX ) First Quarter 2024 Results Key Financial Results Net loss: CA$59.1k (loss narrowed...
NewsfileGenix Announces TSX-V Approval of Warrant Amendments
Vancouver, British Columbia--(Newsfile Corp. - February 6, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that pursuant to its news release of January 18, 2024, the TSX Venture Exchange has approved the Company's application to amend both the exercise price and the warrant accelerator terms, in addition to extending the expiry dates of 3,354,945 previously issued and outstanding warrants (the "Warrants").The current exercise price of th
NewsfileGenix Announces Warrant Repricing and Seeks Extension
Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - Genix Pharmaceuticals Corporation (TSXV: GENX) (OTCQB: GENPF) ("GENIX" or the "Company") announces that the Company has made an application to the TSX Venture Exchange (the "Exchange") to amend the exercise price, the warrant accelerator terms and extend the expiry date of 3,354,945 previously issued and outstanding warrants (the "Warrants").The Corporation is proposing to reduce the exercise price of the warrants from $0.30 per
